Financial and operational impact of PET scan attrition (U.S. market)

1. Executive summary: the high-stakes PET revenue engine

Positron Emission Tomography (PET) is a premier revenue driver for U.S. hospitals and oncology centers. Unlike standard imaging, PET requires large upfront investment in the scanner (commonly $2M+) and in per-patient procurement of time-sensitive radioactive tracers.

• Annual volume: an average U.S. clinic with a fixed PET/CT system performs roughly 1,500 scans per year (~6 per day).
• Gross billing (chargemaster): U.S. hospitals often bill insurers roughly $7,000–$15,000 per PET scan. Specialized tracers (e.g. PSMA for prostate, amyloid for Alzheimer’s pathways) can push charges above $20,000 in some settings.
• Gross revenue (“the collected”): after contracted discounts, U.S. facilities often realize a blended average of ~$3,500–$6,500 per scan. High-end commercial payers sometimes reimburse at double or triple the Medicare rate.
• Profit margin: fixed costs are high, but marginal profit on a completed scan is substantial. A failed appointment is a double loss: foregone high-margin revenue plus the hard cost of a wasted radioactive dose.

2. The problem: “perishable” revenue failure

PET is uniquely exposed to cancellations because the “fuel” — the tracer — is radioactive and decays continuously. If the patient is not on the table at the scheduled time, the facility loses the revenue opportunity and still pays for a dose that cannot be re-sold later.

Primary U.S. failure points

• Metabolic non-compliance: patients miss strict no-sugar / low-carb diets or fasting rules; elevated blood glucose can render FDG unusable for the intended study.
• Insurance / auth friction: late prior-authorization denials or expired certificates of medical necessity — discovered at check-in or the day of service.
• Prep ignorance: vigorous exercise or caffeine (e.g. cardiac PET) inside the restricted window despite written instructions.
• Tracer logistics: the site pays roughly $500–$1,500 per ordered dose whether or not the patient shows.

3. Estimated impact of a 5% cancellation rate (U.S. scale)

For a single U.S. PET imaging suite, 5% attrition is still a major financial line item. Example model:

4. Strategic opportunity: reclaiming the PET margin

In a multi-site U.S. health system — e.g. five PET locations at similar unit economics — the same 5% cancellation pattern implies on the order of $2.25 million in annual profit leakage before any operational fixes.

Recovery math (illustrative): cutting suite-level cancellations from 5% to 2% avoids roughly 45 of the 75 lost slots in the table above — about 60% of the modeled ~$450K annual hit, i.e. on the order of ~$270,000 per suite per year at the same blended economics.

• Digital fasting / carb guides tuned to FDG protocols, with timed nudges.
• Glucose-management reminders and simple self-attestation flows ahead of radiopharmacy commit.
• Real-time “readiness checks” ~24 hours before the dose is ordered from the radiopharmacy, so auth and prep gaps surface while slots can still pivot.

5. Conclusion

Because PET tracers are use-it-or-lose-it assets, ROI on patient preparation is unusually high versus many other radiology lines. In several reasonable models, one prevented cancellation per month can cover the annual cost of a sophisticated patient-engagement platform — before counting softer benefits (better throughput, fewer same-day scrambles, happier technologists).